diprosalic húðlausn
n.v. organon* - betamethasonum díprópíónat; acidum salicylicum - húðlausn
clopidogrel / acetylsalicylic acid mylan
mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - eftir að/asetýlsalisýlsýru mylan er ætlað fyrir efri fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mylan er fastur-skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q-bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.
treo citrus freyðitafla 500/50 mg
viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500/50 mg
hjartamagnýl magasýruþolin tafla 75 mg
teva b.v.* - acidum acetylsalicylicum - magasýruþolin tafla - 75 mg
treo freyðitafla 50 mg/ 500 mg
viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 50 mg/ 500 mg
treo hindbær freyðitafla 500/50 mg
viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 500/50 mg
treo freyðitafla 500 mg/50 mg
viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500 mg/50 mg
calcipotriol/betamethasone teva (calcipotriol/betamethasone ratiopharm) smyrsli 50 míkrog/g + 0,5 mg/g
teva b.v.* - betamethasonum díprópíónat; calcipotriolum inn - smyrsli - 50 míkrog/g + 0,5 mg/g
nordimet
nordic group b.v. - stendur - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - Æxlishemjandi lyf - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
tybost
gilead sciences ireland uc - cobicistat - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.